Alexion Pharmaceuticals Inc. (ALXN). The company posted a more than two-fold rise in net quarterly profit that also topped market estimates, helped by strong global sales of its genetic disorder drug, and raised its full-year view for the second time in less than a month. For the third quarter, the company reported a net income of $65.6 million, or 34 cents a share, compared with $27.9 million, or 15 cents a share, a year ago. The company now sees 2011 earnings of $1.25-$1.28 excluding items, up from earlier outlook of $1.15-$1.20.
ALXN is up 4.00 to 70.03 in premarket trading.
ALXN is Investor's Business Daily's number 1 rated stock.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment